Insider · CIK 0001727334
Chandler Robinson
Files at MNPR (Monopar Therapeutics). First filing Apr 4, 2025, latest Sep 28, 2026.
Chandler Robinson files SEC Form 4 as CEO and director at MNPR (Monopar Therapeutics). Since Apr 4, 2025, Chandler Robinson has reported 0 open-market buys worth $0 and 4 open-market sells worth $39M, the latest filed on Sep 28, 2026.
A track record needs three past buys with six months of prices behind them; Chandler Robinson has 0, so none is measured yet.
The newest scored trade: sold $2.6M of MNPR on Sep 24, 2026, filed Sep 28, 2026, scored 28 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $2.6M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MNPR: Monopar Therapeutics
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Monopar Therapeutics | $2.6M 29,056 shares | -23% | +77% from low-28% from high | |
| 70Notable | MNPRsell Monopar Therapeutics | $35M 550,229 shares | -67% | +1556% from low0% from high | |
| 65Notable | Monopar Therapeutics | $672k 16,800 shares | -19% | +1722% from low-16% from high | |
| 50Moderate | MNPRsell Monopar Therapeutics | $1.2M 33,334 shares | -4% | +1505% from low-26% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 14, 2025 | MNPR Monopar Therapeutics | 16,800 0.27% of outstanding | $672k | Jul 14, 2025 | none |
Transactions
Every row this insider has filed, 31 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +9,801 | - | - | 109,068 | 11 d ago |
| Sep 30, 2026 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -4,344 | $79.67 | $346k | 104,724 | 11 d ago |
| Sep 30, 2026 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitderivative | -9,801 | $0.00 | $0 | 83,602 | 11 d ago |
| Sep 24, 2026 | MNPR Monopar Therapeutics | MOption exercise Common Stock10b5-1 | +14,056 | $30.00 | $422k | 113,323 | 15 d ago |
| Sep 24, 2026 | MNPR Monopar Therapeutics | MOption exercise Common Stock10b5-1 | +15,000 | $14.00 | $210k | 128,323 | 15 d ago |
| Sep 24, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -10,450 | $87.15 | $911k | 117,873 | 15 d ago |
| Sep 24, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -9,638 | $87.96 | $848k | 108,235 | 15 d ago |
| Sep 24, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -8,368 | $88.97 | $745k | 99,867 | 15 d ago |
| Sep 24, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -600 | $89.79 | $54k | 99,267 | 15 d ago |
| Sep 24, 2026 | MNPR Monopar Therapeutics | MOption exercise Stock Optionderivative10b5-1 | -14,056 | $0.00 | $0 | 15,044 | 15 d ago |
| Sep 24, 2026 | MNPR Monopar Therapeutics | MOption exercise Stock Optionderivative10b5-1 | -15,000 | $0.00 | $0 | 27,204 | 15 d ago |
| Jan 28, 2025 | MNPR Monopar Therapeutics | JOther Common Stockindirect: See Footnote | +62,815 | $0.00 | $0 | 62,815 | Jan 30, 2026 |
| Dec 31, 2025 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +8,724 | - | - | 88,276 | Jan 5, 2026 |
| Dec 31, 2025 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -2,558 | $65.30 | $167k | 85,718 | Jan 5, 2026 |
| Dec 31, 2025 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitderivative | -8,724 | $0.00 | $0 | 113,008 | Jan 5, 2026 |
| Dec 2, 2025 | MNPR Monopar Therapeutics | AGrant or award Stock Optionsderivative | +16,753 | $0.00 | $0 | 16,753 | Dec 8, 2025 |
| Dec 2, 2025 | MNPR Monopar Therapeutics | AGrant or award Restricted Stock Unitsderivative | +49,133 | $0.00 | $0 | 121,732 | Dec 8, 2025 |
| Sep 30, 2025 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +8,726 | - | - | 82,198 | Oct 2, 2025 |
| Sep 30, 2025 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -2,646 | $81.67 | $216k | 79,552 | Oct 2, 2025 |
| Sep 30, 2025 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitsderivative | -8,726 | $0.00 | $0 | 72,599 | Oct 2, 2025 |
| Sep 24, 2025 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock | -550,229 | $63.61 | $35M | 272,026 | Sep 26, 2025 |
| Jul 14, 2025 | MNPR Monopar Therapeutics | XIn-the-money exercise Common Stock | +16,800 | $0.01 | $84 | 90,272 | Jul 16, 2025 |
| Jul 14, 2025 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock | -16,800 | $40.00 | $672k | 73,472 | Jul 16, 2025 |
| Jul 14, 2025 | MNPR Monopar Therapeutics | XIn-the-money exercise Stock Optionsderivative | -16,800 | $0.00 | $0 | 0 | Jul 16, 2025 |
| Jun 30, 2025 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +13,344 | - | - | 79,337 | Jul 2, 2025 |
| Jun 30, 2025 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -5,865 | $35.78 | $210k | 73,472 | Jul 2, 2025 |
| Jun 30, 2025 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitsderivative | -13,344 | $0.00 | $0 | 81,325 | Jul 2, 2025 |
| Apr 2, 2025 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock | -33,334 | $35.00 | $1.2M | 822,255 | Apr 4, 2025 |
| Mar 31, 2025 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +4,106 | - | - | 67,197 | Apr 2, 2025 |
| Mar 31, 2025 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -1,204 | $36.41 | $44k | 65,993 | Apr 2, 2025 |
| Mar 31, 2025 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitsderivative | -4,106 | $0.00 | $0 | 94,669 | Apr 2, 2025 |
Questions about Chandler Robinson
Answered from the filings on this page, as of the latest one.
Is Chandler Robinson buying or selling?
In the last 12 months Chandler Robinson reported 0 open-market buys worth $0 and 1 open-market sell worth $2.6M on SEC Form 4; the latest was sold $2.6M of MNPR on Sep 24, 2026. Grants, option exercises and tax withholding are not counted.
How did Chandler Robinson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Chandler Robinson has 0.
Where does Chandler Robinson file Form 4?
Chandler Robinson has filed Form 4 at MNPR (Monopar Therapeutics) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.